Abstract

Nanotechnology offers exciting opportunities in the fight against cancer. New technological breakthroughs have enabled innovative therapeutic applications of nanoparticles and have facilitated diagnostics at the nanoscale. As examples, the delivery of RNA with nanoparticles (in the product patisiran), has been approved by EMA/FDA in 2018, while the first liquid biopsy for prostate cancer based on exosome analysis was launched in 2016.